This article has been updated with comments from Cepheid's CEO, John Bishop.

NEW YORK (GenomeWeb) – Cepheid reported after the close of the market on Tuesday that its fourth-quarter revenues rose 12 percent year-over-year, and attributed the growth to what it called record reagent revenues and GeneXpert system placements.

The Sunnyvale, Calif.-based firm reported revenues of $147.0 million for the three months ended Dec. 31, 2015, up from $131.5 million in Q4 2014 and in line with the consensus analyst estimate of $146.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Sponsored by

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.